Pierre Fabre Pharmaceuticals Inc. announces the FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

MLA

“Pierre Fabre Pharmaceuticals Inc. Announces the FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease.” PR Newswire, 18 July 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.801712239&authtype=sso&custid=ns315887.

APA

Pierre Fabre Pharmaceuticals Inc. announces the FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease. (2024, July 18). PR Newswire.

Chicago

PR Newswire. 2024. “Pierre Fabre Pharmaceuticals Inc. Announces the FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease,” July 18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.801712239&authtype=sso&custid=ns315887.